hVIVO (LON:HVO) Trading Down 45.1% - Time to Sell?

Shares of hVIVO plc (LON:HVO - Get Free Report) traded down 45.1% during mid-day trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.89 ($0.12). 79,176,703 shares traded hands during trading, an increase of 2,238% from the average session volume of 3,386,887 shares. The stock had previously closed at GBX 16.20 ($0.22).

Analyst Upgrades and Downgrades

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday.

hVIVO Stock Performance

The firm's 50 day moving average price is GBX 16.16 and its 200-day moving average price is GBX 18.13. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm has a market capitalization of £61.56 million, a PE ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. On average, research analysts expect that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Transactions at hVIVO

In related news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). Corporate insiders own 14.03% of the company's stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.